EUVIMEDEUVIMED entdecken
Crossref

Relationship between HER2-low status and efficacy of CDK4/6 inhibitors in advanced breast cancer: a real-world study

T Önder, Ö Ateş, I Öner, C Karaçin

International Journal of Clinical Oncology · 2024-07 · 29 (7) · 972-984

DOI: 10.1007/s10147-024-02528-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Clinical Oncology, online erschienen am 30.04.2024. Verfasst von T Önder und 3 weiteren Autor:innen. Beteiligte Einrichtung: Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey. ondertugba111@gmail.com. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 59 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS AND OBJECTIVES: Human epidermal growth factor receptor 2 (HER2)-low breast cancer (BC) is a new entity considered a biologically distinct subtype from HER2-zero BC. However, the importance of HER2 low expression on the activity of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) remains unclear. METHODS/MATERIALS: We conducted a single-center retrospective study including hormone receptor-positive (HR +) /HER2- metastatic BC (mBC) patients treated with CDK4/6i plus endocrine treatment (ET) as first-line therapy. Clinical outcomes were analyzed according to HER2 expression. RESULTS: 258 women were analyzed with a median follow-up of 25.4 months; 39.9% had HER2 low, and 60.1% had HER2 zero BC. Median progression-free survival (mPFS) in the HER2-low group was 27.6 months compared with 44.3 months in the HER2-zero group (p = 0.341). In patients receiving ribociclib, the mPFS in the HER2-low group was 24.2 months compared with 53.1 months in the HER2-zero group (multivariate-adjusted HR: 1.981, 95 Cl 1.094-3.586; p = 0.024). The survival probabilities at 24, 36 and 48 months for the HER2 low and HER2 zero groups were 82%, 69%, 69% and 83%, 75% and 69%, respectively (p = 0.336). Objective response rate (p = 0.179) and disease control rate (p = 0.338) did not significantly differ between HER-2-low and HER-2-zero groups. CONCLUSIONS: The mPFS in the Her2-zero group was almost twice that of the Her2-low group, but the difference was not statistically significant. mPFS was significantly longer in the HER2-zero group compared to the HER2-low group in patients receiving ribociclib. More prospective studies are needed to understand the actual consequences of this biomarker.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Protein Kinase InhibitorsPurinesAminopyridinesHumansFemaleMiddle AgedRetrospective StudiesAgedAdultProgression-Free SurvivalAged, 80 and overAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

Breast cancerCDK 4/6 inhibitorHER2-lowHER2-zero

Substanzen

Erb-b2 Receptor Tyrosine KinasesCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Protein Kinase InhibitorsPurinesAminopyridinesERBB2 protein, humanribociclibCDK4 protein, humanCDK6 protein, human

Autor:innen und Institutionen

  • Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey. ondertugba111@gmail.com.
  • Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey.

Zitieren

APA

Önder, T., Ateş, Ö., Öner, I., & Karaçin, C. (2024). Relationship between HER2-low status and efficacy of CDK4/6 inhibitors in advanced breast cancer: a real-world study. International Journal of Clinical Oncology, 29(7), 972-984. https://doi.org/10.1007/s10147-024-02528-w

Vancouver

Önder T, Ateş Ö, Öner I, Karaçin C. Relationship between HER2-low status and efficacy of CDK4/6 inhibitors in advanced breast cancer: a real-world study. International Journal of Clinical Oncology. 2024;29(7):972-984. doi:10.1007/s10147-024-02528-w

BibTeX
@article{nder2024,
  author = {Önder, T and Ateş, Ö and Öner, I and Karaçin, C},
  title = {Relationship between HER2-low status and efficacy of CDK4/6 inhibitors in advanced breast cancer: a real-world study},
  journal = {International Journal of Clinical Oncology},
  year = {2024},
  volume = {29},
  number = {7},
  pages = {972--984},
  doi = {10.1007/s10147-024-02528-w}
}
Kostenlos starten →